Intellectual Property India Publishes Patent Application for Ginger Derived Exosome Like Nanoparticles Ameliorate Insulin Resistance In-Vitro And Restores Glucose And Lipid Homeostasis In Type 2 Diabetic Mice Model.

MUMBAI, India, July 31 -- Intellectual Property India has published a patent application (202411098742 A) filed by National Agri-Food Biotechnology Institute Nabi on December 13, 2024, for Ginger Derived Exosome Like Nanoparticles Ameliorate Insulin Resistance In-Vitro And Restores Glucose And Lipid Homeostasis In Type 2 Diabetic Mice Model..

Inventors include Geetika Bajaj; Diksha Choudhary; Vikas Rishi; and Nitin Kumar Singhal.

The application for the patent was published on July 24, 2026, under issue no. 30/2026.

Abstract: This invention focuses on the therapeutic effects of ginger-derived exosomes (G-ELNs) to improve glucose and lipid metabolism in the type 2 diabetes mellitus. Studies demonstrated that G-ELNs enhanced insulin sensitivity in insulin-resistant HepG2 cells by enhancing the expression of p-Akt-2, thus reducing gluconeogenesis and oxidative stress. In T2DM mice models, G-ELNs restored hepatic glucose and lipid homeostasis by modulating key metabolic enzymes and pathways. Thus, this invention sheds light on an innovative, safer approach for managing T2DM and associated metabolic disorders.

Disclaimer: Curated by HT Syndication.